Kynurenine Pathway Modulators for Neurodegeneration

Kynurenine Pathway Modulators for Neurodegeneration

Overview

Kynurenine Pathway Modulators for Neurodegeneration

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Kynurenine Pathway Modulators for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Compound</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Eoselodentib (LYNZE-LYM)</td>
<td>IDO1/TDO</td>
</tr>
<tr>
<td class="label">PF-06840003</td>
<td>IDO1</td>
</tr>
<tr>
<td class="label">BMS-986205</td>
<td>IDO1</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Properties</td>
</tr>
<tr>
<td class="label">JNJ-54178610</td>
<td>Brain-penetrant KMO inhibitor</td>
</tr>
<tr>
<td class="label">KMO inhibitor (UCB-61163)</td>
<td>Selective, brain-penetrant</td>
</tr>
<tr>
<td class="label">Nicotinylalanine</td>
<td>Non-selective KMO inhibitor</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Compound</td>
</tr>
<tr>
<td class="label">KMO inhibition</td>
<td>JNJ-54178610</td>
</tr>
<tr>
<td class="label">Kynurenine administration</td>
<td>L-kynurenine</td>
</tr>
<tr>
<td class="label">Direct KYNA analogs</td>
<td>KYN-210, Br-KYN</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>KAT-II upregulation</td>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Compound</td>
</tr>
<tr>
<td class="label">KMO inhibition</td>
<td>Various</td>
</tr>
<tr>
<td class="label">QA antibodies</td>
<td>None approved</td>
</tr>
<tr>
<td class="label">Antioxidants</td>
<td>CoQ10, vitamin E</td>
</tr>
<tr>
<td class="label">NMDA antagonists</td>
<td>Memantine</td>
</tr>
<tr>
<td class="label">Trial ID</td>
<td>Compound</td>
</tr>
<tr>
<td class="label">NCT02497114</td>
<td>KMO inhibitor</td>
</tr>
<tr>
<td class="label">NCT03818386</td>
<td>IDO1 inhibitor</td>
</tr>
<tr>
<td class="label">NCT04185238</td>
<td>L-kynurenine</td>
</tr>
</table>

The kynurenine pathway represents a critical metabolic axis linking tryptophan catabolism to neuroinflammation and neurodegeneration. This pathway generates several neuroactive metabolites—including [kynurenic acid](/mechanisms/kynurenine-pathway) (KYNA) and quinolinic acid (QA)—that have opposing effects on neuronal health. Therapeutic modulation of this pathway has emerged as a promising strategy for treating neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), corticobasal degeneration (CBS), progressive supranuclear palsy (PSP), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and Huntington's disease (HD).

The therapeutic rationale centers on reducing neurotoxic metabolites (particularly quinolinic acid) while enhancing neuroprotective ones (kynurenic acid), or directly inhibiting rate-limiting enzymes like indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO).

Therapeutic Mechanisms

1. IDO/TDO Inhibitors

Indoleamine 2,3-dioxygenase (IDO) and Tryptophan 2,3-dioxygenase (TDO) catalyze the first and rate-limiting steps in kynurenine pathway activation. Overexpression of these enzymes in neurodegenerative conditions leads to:

• Depletion of tryptophan (essential for serotonin synthesis)
• Accumulation of neurotoxic kynurenine metabolites
• Immune suppression via tryptophan starvation
• Neuroinflammation amplification

Clinical evidence:

• IDO activity is elevated in AD, PD, and ALS brain tissue
• Genetic variants in IDO1 associated with PD risk
• TDO inhibition reduces neuroinflammation in animal models

2. Kynurenine 3-Monooxygenase (KMO) Inhibitors

[KMO](/mechanisms/kynurenine-pathway) converts kynurenine to 3-hydroxykynurenine, which subsequently forms quinolinic acid—a potent NMDA receptor agonist and oxidative stress generator. KMO inhibition shifts metabolism toward kynurenic acid production.

Key compounds:

Advantages of brain-penetrant KMO inhibitors:

• Reduce downstream neurotoxic metabolites (quinolinic acid, 3-HK)
• Increase kynurenic acid (neuroprotective)
• Potential for disease modification in HD, PD, AD

3. Kynurenic Acid Augmentation

[Kynurenic acid](/mechanisms/kynurenine-pathway) acts as an endogenous NMDA receptor antagonist, providing neuroprotection against excitotoxicity. However, KYNA poorly crosses the blood-brain barrier, limiting therapeutic utility.

Strategies under investigation:

4. Quinolinic Acid Reduction

Quinolinic acid (QA) is a neurotoxic metabolite that:

• Overstimulates NMDA receptors (excitotoxicity)
• Generates reactive oxygen species
• Disrupts mitochondrial function
• Promotes tau phosphorylation
• Activates glial cells

Evidence by Disease

Alzheimer's Disease (AD)

Pathology:

• Elevated quinolinic acid in AD brain and CSF
• Increased IDO activity in microglia surrounding plaques
• Kynurenine/tryptophan ratio correlates with disease severity

• KMO inhibitors reducing tau pathology in AD models
• KYNA augmentation protecting against Aβ toxicity

Parkinson's Disease (PD)

Pathology:

• Elevated kynurenine in PD substantia nigra
• IDO1 upregulation in PD microglia
• Quinolinic acid contributes to dopaminergic neuron death

• KMO activity elevated in PD CSF
• Kynurenine levels correlate with motor severity

Corticobasal Degeneration (CBS) / Progressive Supranuclear Palsy (PSP)

Pathology:

• Limited direct evidence, but tauopathies show kynurenine pathway activation
• Neuroinflammation is prominent in CBS/PSP

Amyotrophic Lateral Sclerosis (ALS)

Pathology:

• Markedly elevated quinolinic acid in ALS CSF and spinal cord
• IDO1 activation in motor neurons and glia
• Correlation between QA levels and disease progression

• KMO inhibitors in development (preclinical)
• No completed ALS trials yet

Frontotemporal Dementia (FTD)

Pathology:

• Elevated kynurenine in FTD brain
• IDO1 activation in FTD frontal cortex

Huntington's Disease (HD)

Pathology:

• Most extensively studied in kynurenine pathway
• Dramatically elevated quinolinic acid in HD brain and CSF
• KMO is a validated therapeutic target

• KMO inhibitors (NCT02497114) — reduced 3-HK in CSF
• No disease-modifying effect demonstrated yet

Drug Candidates in Detail

Eoselodentib (LYNZE-LYM)

• Target: IDO1 and TDO dual inhibitor
• Company: Lynzyme
• Stage: Preclinical
• Evidence: Reduces kynurenine accumulation, increases serotonin precursors
• Challenges: Brain penetration, selectivity

JNJ-54178610

• Target: Kynurenine 3-monooxygenase (KMO)
• Company: Janssen
• Stage: Preclinical
• Evidence: Reduced quinolinic acid in PD models, neuroprotection in HD models
• Advantages: Brain-penetrant, selective

Tryptophan Restriction (Dietary/Nutritional)

• Target: Substrate availability
• Evidence: Low-tryptophan diets reduce kynurenine in animal models
• Approach: Dietary intervention, nutritional supplements
• Challenges: Non-specific, may affect essential tryptophan metabolism

Clinical Trial Landscape

Therapeutic Implications

Biomarkers for Target Engagement

• Quinolinic acid: CSF QA levels (reduces with KMO inhibition)
• Kynurenic acid: CSF KYNA levels (increases with treatment)
• Kynurenine/tryptophan ratio: Plasma/CSF ratio as IDO activity marker

Combination Therapy Potential

• With anti-inflammatories: Synergistic effect on neuroinflammation
• With antioxidants: Protect against QA-induced oxidative stress
• With disease-modifying therapies: Complementary mechanisms

Challenges

See Also

• [Kynurenine Pathway in Neurodegeneration](/mechanisms/kynurenine-pathway)
• [Neuroinflammation Pathway](/mechanisms/neuroinflammation-pathway)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Huntington's Disease](/diseases/huntingtons)
• [ALS](/diseases/amyotrophic-lateral-sclerosis)

External Links

• [ClinicalTrials.gov - Kynurenine pathway](https://clinicaltrials.gov/)
• [KMO Inhibitor Development (Nature 2019)](https://www.nature.com/articles/s42003-019-0520-5)
• [Kynurenine Pathway Review (Life 2025)](https://www.mdpi.com/2075-1729/16/2/266)

References